In this interview with The Dales Report, InMed CEO Eric A. Adams talks about how the scalability of synthesized rare cannabinoids will make them more affordable.
Read the article and watch the full video at The Dales Report.
In this interview with The Dales Report, InMed CEO Eric A. Adams talks about how the scalability of synthesized rare cannabinoids will make them more affordable.
Read the article and watch the full video at The Dales Report.
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the role of the endocannabinoid system? How do cannabinoids interact with the
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What are illegal synthetic cannabinoids? How are illegal synthetic cannabinoids different from bioidentical synthesized
© Copyright 2023 InMed Pharmaceuticals Inc.
"*" indicates required fields